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Abstract
Background: Schistosomes are chronic intravascular helminth parasites of humans causing a heavy burden of disease
worldwide. Diagnosis of schistosomiasis currently requires the detection of schistosome eggs in the feces and urine of
infected individuals. This method unreliably measures disease burden due to poor sensitivity and wide variances in egg
shedding. In vivo imaging of schistosome parasites could potentially better assess disease burden, improve management of
schistosomiasis, facilitate vaccine development, and enhance study of the parasite’s biology. Schistosoma mansoni (S.
mansoni) have a high metabolic demand for glucose. In this work we investigated whether the parasite burden in mice
could be assessed by positron emission tomography (PET) imaging with 2-deoxy-2[
18F]fluoro-D-glucose (FDG).
Methodology/Principal Findings: Live adult S. mansoni worms FDG uptake in vitro increased with the number of worms.
Athymic nude mice infected with S. mansoni 5–6 weeks earlier were used in the imaging studies. Fluorescence molecular
tomography (FMT) imaging with Prosense 680 was first performed. Accumulation of the imaging probe in the lower
abdomen correlated with the number of worms in mice with low infection burden. The total FDG uptake in the common
portal vein and/or regions of elevated FDG uptake in the liver linearly correlated to the number of worms recovered from
infected animals (R
2=0.58, P,0.001, n=40). FDG uptake showed a stronger correlation with the worm burden in mice with
more than 50 worms (R
2=0.85, P,0.001, n=17). Cryomicrotome imaging confirmed that most of the worms in a mouse
with a high infection burden were in the portal vein, but not in a mouse with a low infection burden. FDG uptake in
recovered worms measured by well counting closely correlated with worm number (R
2=0.85, P,0.001, n=21). Infected
mice showed a 32% average decrease in total FDG uptake after three days of praziquantel treatment (P=0.12). The total
FDG uptake in untreated mice increased on average by 36% over the same period (P=0.052).
Conclusion: FDG PET may be useful to non-invasively quantify the worm burden in schistosomiasis-infected animals. Future
investigations aiming at minimizing non-specific FDG uptake and to improve the recovery of signal from worms located in
the lower abdomen will include the development of more specific radiotracers.
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Introduction
Schistosomiasis is a disease of chronic morbidity affecting the
liver, mesentery, and urogenital tract of infected individuals,
caused by the parasitic trematode worms, schistosomes. In certain
endemic regions like China, the increasing focus on antischisto-
somal chemotherapy over the past 30 years has dramatically
decreased infection rates [1,2]. However, global prevalence still
exceeds 207 million people because of post-treatment re-infection
and inadequate control measures, leaving over 779 million people
at risk for future infection [3]. In addition, researchers familiar
with the true morbidity of schistosomiasis have indicated a greater
disability-adjusted life year (DALY) than was previously thought,
estimating up to a 70 million DALY burden [4]. Potential
resistance to praziquantel, the current treatment standard also
became an emerging concern in 1991 when an initial trial in
Senegal reported low cure rates, although these results have not
been confirmed [2]. A reduced susceptibility to praziquantel
among certain naturally occurring Kenyan isolates of Schistosoma
mansoni (S. mansoni) was also reported [5].
Eradicating schistosomiasis will require a multifaceted approach
that emphasizes the development of new drugs, vaccines [6] and
better diagnostic methods [7,8]. Currently, such advances are
stymied by the inability to accurately assess worm burden in
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the techniques of choice for diagnosis and testing candidate drug
efficacy. These methods are unfortunately time-consuming, labor-
intensive, costly, and unreliable because of daily variability and
poor sensitivity [7,9–12]. For example, when host egg excretion
falls below 100 eggs per gram of stool (equivalent to an infection
burden below 40 worms), it is increasingly difficult to accurately
assess the disease burden [7,8,13]. These shortcomings may
overestimate treatment efficacy and delay the detection of
praziquantel-resistant strains. Immunodiagnostic techniques are
becoming increasingly popular because of their high sensitivity
and ease of use, but they rely on circulating antibodies, which have
a significant time-delay with respect to infection and treatment
[7,14–16]. Furthermore, immunodiagnostic measures are of little
use in vaccination trials because subjects have elevated antibody
levels. In order to expedite research, vaccine development, and
diagnosis of schistosomiasis, these challenges necessitate the
development of better tools for determining infection burden.
In the past decade, small animal molecular imaging probes have
achieved considerable success for non-invasively assessing disease
status. Fluorescence molecular tomography (FMT) using near-
infrared imaging probes activated by the abundant cathepsins in
the schistosomes’ digestive tract can quantify the worm burden in
murine models of schistosomiasis [17–19]. However, this technol-
ogy currently cannot be applied to human subjects. Positron
emission tomography (PET) imaging is useful in measuring cellular
metabolism and has emerged as a key non-invasive imaging tool
for the diagnosis, staging and evaluation of treatment response for
cancer in human patients [20,21]. We hypothesized that this in vivo
molecular imaging technology may also provide a tool to detect
and quantify adult helminth parasites.
Bueding performed the first worm physiology experiments in
1950 and found schistosomes to be demanding consumers of
glucose, metabolizing their dry body weight in roughly four hours
[22]. We reasoned that 2-deoxy-2[
18F]fluoro-D-glucose (FDG), a
glucose analogue clinically used as a PET radiotracer for glucose
metabolism, could be useful for imaging adult schistosomes. The
following work assesses the usefulness of FDG PET to quantify S.
mansoni worm burden and treatment efficacy in a mouse model of
schistosomiasis.
Materials and Methods
In vitro FDG Uptake
Unless mentioned otherwise, chemicals and reagents were
obtained from Invitrogen (Carlsbad, Ca). In vitro uptake experi-
ments in adult schistosomes were conducted using both female and
male, paired and unpaired worms perfused from 5-weeks post-
infection CD-1 outbred mice (see below for infection protocol).
Perfused worms were washed 4 times in 1.5 ml eppendorf tubes
with 1x phosphate-buffered saline (PBS) in which glucose was
added at a concentration of 1 g/L. Tubes were arranged in
triplicate, each with either 1 or 5 worms per tube. Six hundred
microliters of Dulbecco’s Modified Eagle Medium (DMEM) low
glucose medium (1 g/L) containing 150 mCi of FDG was added to
each tube and incubations were carried out at room temperature.
Clinical grade FDG was supplied by PETNET solutions/Siemens
(Knoxville, TN) with a specific activity larger than 2,000 Ci/
mmol. After one hour, each tube was washed four times using cold
1x PBS with 1 g/L of glucose. The tubes were then placed in a
Wallac 1282 CompuGamma well counter (Perkin Elmer Life
Science; Waltham, Ma) to measure gamma rays emitted from
18F
decay in counts per minute (cpm). In some experiments, 20 mlo f
10% sodium iodide and 5% iodine was added to 250 ml of PBS
containing single adult worms for 5 minutes. The killed worms
were washed twice in PBS prior to adding the FDG.
Animals
Six-week old female athymic nude mice (nu/nu) were anesthetized
u s i n ga5 0 0 - ml solution of avertin (1:1 tert-amyl alcohol:tribromoetha-
nol; Sigma Aldrich; St-Louis, MO) diluted to 2.5%. Mice were
infected percutaneouslywith the aim to obtaina widerange of parasite
burdens. The animals were kept in isolation facilities for 5–6 weeks
until imaging. To minimize background fluorescence during FMT
imaging studies, mice were switched to a low-fluorescence diet (Harlan
laboratories; Indianapolis, IN) three days prior the experiments. Mice
were deprived of food overnight before imaging experiments. All
animal studies were conducted in accordance with the regulations and
guidelines set forth by the Institutional Animal Care and Use
Committee (IACUC) at Case Western Reserve University.
Fluorescence Molecular Tomography and Magnetic
Resonance Imaging Studies
Eight infected and two uninfected (control) mice were injected
in the tail vein with 2 nmol of Prosense 680 (Visen Medical Inc.;
Bedford, MA) diluted in 100 ml of sterile 1x PBS. Twenty-four
hours after injections, mice were anesthetized with isoflurane
(Aerrane; Baxter; Deerfield, IL), placed in imaging cassettes and
imaged on a FMT 2500 imaging system (Visen Medical Inc.;
Bedford, MA) using the 685 nm channel. Anesthesia was
maintained with 1.5% isoflurane and oxygen (1 L/min) flowing
within the imaging chamber throughout the acquisition. After
FMT imaging, wells on the half of the imaging cassette were filled
with a solution of 0.05% magnevist (gadopentetate dimeglumine;
Bayer Healthcare Pharmaceuticals; Montville, NJ) diluted in
distilled water for co-registration purposes. The cassette was
transferred to a magnetic resonance imaging (MRI)-compatible
bed and imaged on a Biospin 7.0T MRI scanner (Bruker; Billerica,
MA). T2-weighted images using a multi-slice multi-echo (MSME)
sequence were acquired, producing a set of coronal images
(repetition time (TR)=1250 ms, echo time (TE)=15 ms, flip
angle=90u, voxel size=0.031260.031260.05 cm). Anesthesia
Author Summary
Schistosomiasis is a well studied parasitic disease that is far
from eradication despite the development of an effective
treatment. The lack of an efficacious vaccine and high re-
infection rates after treatment are major factors in its
intractable worldwide prevalence. A non-invasive imaging
technique like positron emission tomography (PET) could
give clinicians and researchers a quantitative and visual
tool to characterize the worm burden in infected
individuals, determine the efficacy of a candidate vaccine,
and provide information about parasite migration patterns
and basic biology. We are therefore proposing the novel
application of PET imaging to schistosomiasis in order to
advance the management and research of this infectious
disease. Herein, we demonstrate that schistosome para-
sites take up 2-deoxy-2[
18F]fluoro-D-glucose (FDG). FDG
uptake in regions adjacent to or within the liver linearly
correlate with the worm number in infected mice, but the
correlation was stronger in mice with high infection
burdens. We anticipate that this research is a first step in
the development of more specific radiotracers optimized
for schistosomiasis, and will eventually translate to human
studies.
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recover from anesthesia in their cages for at least one hour before
microPET (mPET) imaging. FMT and MRI images were co-
registered using COMKAT, a Matlab-based general-purpose
compartment modeling software tool [23].
mPET imaging
Thirty-five infected and four uninfected (control) mice were
used in the mPET imaging studies (four of the infected mice were
scanned twice at an interval of three days and ten other mice had
been scanned with FMT and MRI). One hundred minutes before
mPET imaging, mice were anesthetized with isoflurane mixed with
oxygen via isolated chambers, titrating to a respiratory rate of one
breath per second. Periorbital injections of FDG dissolved in
100 ml of sterile saline were administered 90 min before imaging at
a target dose of 25 mCi per gram of body weight. Mice were kept
under anesthesia with isoflurane until mPET imaging to minimize
muscular uptake of the tracer. Twenty minutes before imaging, a
26 gauge fluorinated-ethylene-propylene (FEP) monoject veteri-
nary I.V. catheter coated with an inert lubricant was inserted into
the bladder through the urethra. Urine was removed 5 min prior
to imaging with the help of gravity to minimize imaging artifacts
caused by high FDG concentration in the bladder. mPET imaging
was carried out using a Siemens Concord R4 microPET system
(Siemens Solutions, Knoxville, TN). The imaging protocol
consisted of a 45-min emission scan followed by a 10-min
transmission scan using the
57Co point source for attenuation
correction. The images were reconstructed using a 2D ordered
subset expectation maximization (OSEM) algorithm, yielding a
volume of 1286128663 voxels with a voxel size of
0.8560.8561.21 mm and a spatial resolution of approximately
1.84 mm [24]. The mPET scanner was calibrated prior to the
imaging studies using a phantom with a known radioactivity
concentration measured by a dose calibrator. Verification scans
confirmed that the relative error in quantifying the true
radioactivity (as measured with a dose calibrator) in a phantom
by measuring it using mPET imaging was less than 5%.
Praziquantel Treatment
Six infected mice were treated with praziquantel using oral
gavage. Praziquantel was diluted in 1x PBS, and titrated to
250 mg/kg body mass. Treatments were administered 72, 48, and
24 hours prior to re-imaging. mPET imaging was carried out as
described above before and after treatment.
Worm Perfusion
Perfusions were conducted using a 5-ml syringe of citrate
solution infused through the right heart ventricle after mice were
euthanized with a sodium pentobarbital cocktail. The portal vein
was ruptured and the perfusate was collected in a sterile culture
plate. Worms and worm pairs were counted and transferred to a
1.5 ml eppendorf tube. Background radioactive signal was washed
from worms using an isotonic glucose solution before measuring
the radioactivity levels by well counting.
Cryomicrotome Imaging
To localize schistosomes in our mouse model of S. mansoni
infection, two infected mice (one of which had been imaged with
FMT, MRI and mPET) were fixed in OCT, flash frozen in liquid
nitrogen and stored at 280uC. The frozen blocs were imaged
using a cryomicrotome imaging system developed in house [25].
Bright field color images were collected at 15.6-mm resolution and
the thickness of each section was 40 mm.
Autoradiography
One infected mouse died approximately 60 min after FDG
injection and was therefore not imaged. The liver and digestive
tract were rapidly removed and exposed for 30 min to a Molecular
Dynamics mounted storage phosphor screen (General Electric
Healthcare; Piscataway, NJ) for autoradiography. After exposure,
the phosphor screen was imaged with a Typhoon imaging system
(General Electric Healthcare; Piscataway, NJ).
Microscopy
The livers of 6 mice were removed after perfusion and kept
overnight in paraformaldehyde. The livers were transferred to a
30% sucrose solution overnight. Fixed tissues were embedded in
OCT and kept at 280uC. Several 10 mm-thick sections from
different areas of the liver were mounted on glass slides using a
CM 3050 S cryostat (Leica; Bannockburn, IL) for hematoxylin and
eosin (H&E) staining. Perfused worms were also directly mounted
on glass slides after FMT and PET imaging. A DM 4000B
microscope (Leica; Bannockburn, IL) equipped with a Cy5 filter
(663–738 nm band-pass) was used to image all sections. Exposure
times for the acquisition of near-infrared images of Prosense 680-
labeled worms were set to 50 ms and bright field images were
acquired to register fluorescent images with soft tissues using the
QCapturePro software (QImaging Corporation; Surrey, BC,
Canada).
Quantitative and Statistical Analyses
Three-dimensional regions of interest (ROIs) were drawn
around the lower abdomen of the mice imaged with FMT to
exclude background signal from the liver. Voxels with values
greater than two times the average signal in the lower abdomen of
the control mice were used for quantification as previously
described [17]. Adjusting the display intensity when needed, ROIs
were manually drawn around the portal vein and, if present,
around areas of increased FDG uptake within the liver
parenchyma using ASIPro VM 6.3.3.0 (Siemens Solutions,
Knoxville, TN). In some cases, the internal organs had shifted as
a result of animal manipulations prior to imaging and the location
of the ROIs was determined using the best judgment from the
user. Areas of high FDG uptake within the small intestines or
colon as determined by careful examination of multiple adjacent
sections were excluded. All radioactivity measurements were
decay-corrected to the scan start time for comparison. Statistical
data were generated using Origin 8.1 (OriginLab; Northampton,
MA). Unpaired and paired t-tests were used to examine the
differences between groups in the in vitro uptake and praziquantel
treatment experiments, respectively. P-values#0.05 were consid-
ered significant. The square of the Pearson’s product-moment
correlation (R
2) was used to determine correlation between
measured signals and worm burden.
Results
In vitro uptake of FDG was examined for adult stage S. mansoni
(Figure 1). The uptake in single iodine-killed worms was
significantly lower than that in untreated single adult worms
(P=0.04). The total uptake by 5 worms was 3.9 times greater than
that by single worms (P=0.002). Based on the 60-min incubation
experiments with 5 worms, the average radioactivity per adult
worm was 54 nCi, which would be sufficient for detection by
mPET imaging.
Whole animal FMT and MRI scans were performed in two
control and eight infected mice (5–6 weeks after infection) and the
images were co-registered to provide an anatomical context for the
In Vivo FDG-PET Imaging of Schistosomes
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moderate and high fluorescence levels were observed in the mid-
section of the abdomen in control and infected mice (Figure 2A).
Anatomical information from MRI confirmed that the most
intense fluorescence signals were originating from regions within
or adjacent to the liver in infected mice. Liver expresses relatively
high levels of the proteases targeted by Prosense probes. Signals of
low, but variable intensity were also observed in the lower
abdomen of all mice. Worms were collected after imaging and
placed on a glass slide. Microscopy demonstrated high fluores-
cence in the digestive tracts of perfused schistosomes (Figure 2B).
Adult S. mansoni parasites are abundant in cathepsins, which
supports the basis for imaging schistosomiasis in vivo with a
fluorescent probe activated by proteases. Total probe accumula-
tion in the lower abdomen regions was previously found to
correlate with worm burden [17]. We did not find a linear
correlation between probe levels in the lower abdomen and worm
burden (R
2=0.009, P=0.80, n=10; Figure 2C). However, when
only considering mice with less than 60 worms (a range
comparable to that previously reported [17]) and excluding
control mice from the analysis as was done in [17], a linear
correlation between probe levels and the lower abdomen and the
number of worms was observed (R
2=0.67, P=0.09, n=5;
Figure 2C, inset).
Figure 1. In vitro FDG uptake by S. mansoni. FDG uptake in counts
per minute (cpm) after 60 min incubations of 5-weeks post-infection
hepatic young adult-stage schistosomes (live). Iodine killed parasites
(dead) of the same developmental age were used as negative controls.
Error bars represent the standard deviation (n=3 experiments each).
doi:10.1371/journal.pntd.0000827.g001
Figure 2. FMT and MRI of mice infected with S. mansoni. (A) Uninfected and mice with different worm burdens were scanned 24 hours after
Prosense 680 injections. MRI was also performed on the same mice to provide anatomical references. Arrows indicate fluorescence in the lower
abdomen. Arrowheads designate areas of fluorescence in the liver. The dotted boxes indicate the three dimensional ROIs used to quantify the probe
amount. Intensity scale [250 (blue)–1500 (red) nM]. (B) Worms were collected on glass slides after perfusion for microscopy. Bright field (BF) and
fluorescent images using the Cy5 filter (Cy5) and 50 ms exposures were acquired and co-registered to show that fluorescence was originating in the
worms’ digestive tract. A male-female pair is shown here. Scale bar=100 mm. (C) Relationship between the total probe amount in the lower abdomen
and the number of worms when considering all mice (n=10; graph) and only infected mice with less than 60 worms (n=5; blue inset).
doi:10.1371/journal.pntd.0000827.g002
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imaging would allow noninvasive quantification of adult S. mansoni
in infected mice. Four control and 35 infected mice were included
in these studies. These included a subset of ten animals (2 control
and 8 infected mice) that also underwent FMT imaging as
described above. One of the infected mice died approximately
60 min after FDG injection and could not be imaged. In another
case, the animal (high infection burden) died before FDG injection
so the liver was removed and processed for histology. Four mice
were scanned twice at 3-day intervals and one mouse was not
perfused, but fixed in OCT after mPET imaging for whole body
cryomicrotome imaging, a technique that allows microscopic
examination of the entire or regional areas of the interior of the
mouse [25]. Forty datasets were thus included in the quantitative
studies. Nineteen mice had an infection burden below 40 worms
while 17 mice carried between 50 and 242 worms. Intense
radioactive signals were observed in the heart, kidneys, bladder
and regions of the lower abdomen in control and infected mice
(Figure 3A, arrowheads). Autoradiography of the liver and
digestive tract in the mouse that died 60 min after FDG injection
revealed that the areas of high radioactivity accumulation in the
lower abdomen corresponded mainly to the colon and, to a lesser
extent, the small intestines (Figure 3B), while the radioactivity
levels in the liver were relatively low (not shown). Moderate
radioactivity accumulation was observed in small regions inferior
to the liver, slightly anterior to the kidneys and superior to the
colon (Figure 3A, arrows). In a few mice, abnormal radioactivity
accumulation was found in some regions of the liver (Figure 3A,
arrows).
Cryomicrotome imaging was carried out after FDG-mPET
scans in one mouse with a low (which did not undergo FDG-mPET
scanning) and one mouse with a high infection burden. The
worms could be readily visualized by their white soft tissue
appearance and dark digestive tract containing heme pigment. In
the mouse with a low infection burden, only a few worms were
seen in the liver parenchyma. We did not find any schistosomes in
the mesentery (not shown), but this was only in one animal. In the
mouse with a high infection burden, a high number of worms were
found in the common portal vein (Figure 3C, arrows). Only a few
worms were seen in the liver and scattered in the mesentery
(Figure 3D, arrows). H&E sections of the liver of the mouse that
died before FDG injection (which had a high target infection
burden) confirmed the presence of worms in branches of the portal
vein in the liver (Figure 3E). The livers from five other infected
mice were also processed for histology after perfusion. Examina-
tion of the H&E sections revealed the absence of worms in the liver
Figure 3. FDG-mPET imaging of mice infected with S. mansoni. (A) mPET scans were acquired in control and infected mice 90 min after FDG
injection. Arrows indicate areas of moderate uptake adjacent to the liver or areas of increased uptake in the liver parenchyma around which ROIs
were drawn to quantify FDG uptake (Figure S1). Arrowheads indicate areas of high uptake in the lower abdomen. The mouse with 104 worms had
also been imaged with FMT/MRI (Figure 2). Note that mice were in prone position for mPET scanning and in supine position for FMT/MRI scanning.
Intensity scale [0 (black)–2610
4 (white) nCi/cc]. (B) Photograph of the digestive tract of an infected animal that was removed 60 min after FDG
injection (upper panel) and exposed to a phosphor screen for autoradiography showing high FDG uptake in the colon and diffuse FDG uptake in
other parts of the digestive tract (lower panel). (C) Cryomicrotome imaging of a mouse with a heavy infection burden. A high number of worms were
found in the common portal vein (arrow). (D) Cryomicrotome imaging of the lower abdomen in the same animal showed the presence of a small
number of worms scattered in the mesentery (arrows). (E) Worms were found in the liver of one infected mouse that died before FDG injection. H&E
staining; scale bar=100 mm. (F) Lack of an overt inflammatory response to an ova in the liver (H&E staining). Scale bar=100 mm.
doi:10.1371/journal.pntd.0000827.g003
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an overt inflammatory response (Figure 3F) indicating that regions
of abnormal FDG uptake in the liver are unlikely due to
granulomatous response to ova. The absence of worms from the
mesentery after perfusion was confirmed by careful visual
inspection.
Because of high background uptake in the colon and small
intestines, three-dimensional ROIs were only drawn around the
common portal vein, inferior to the liver and in areas of increased
uptake in the liver, if present (Figure S1). A linear correlation
between the total radioactivity within ROIs and the number of
worms was observed (R
2=0.58, P,0.001, n=40; Figure 4A). The
background FDG uptake in the common portal vein (y-intercept)
was approximately 110 nCi. An even stronger linear relationship
between total radioactivity within ROIs and the number of worms
was observed in mice with more than 50 worms (R
2=0.85,
P,0.001, n=17; Figure 4A, inset). The radioactivity levels in the
schistosomes from 21 of the infected mice were directly measured
by well counting after perfusion. There was a strong linear
relationship between the measured radioactivity levels in perfused
worms and the number of worms (R
2=0.85, P,0.001, n=21;
Figure 4B). The total radioactivity within ROIs correlated with the
measured radioactivity levels in perfused worms (R
2=0.74,
P,0.001, n=21; Figure 4C). However, the radioactivity measured
by mPET was in general less than that in the perfused worms.
Praziquantel treatment studies were finally performed to
investigate the usefulness of FDG-PET for assessing treatment
efficacy (Figure 5A). Four infected mice did not receive treatments
and were scanned twice, at three-day intervals, serving as positive
controls (* and **; Figure S1). Over the three-day period, FDG
uptake in the area of the common portal vein increased by 36% on
average in untreated mice (P=0.052; Figure 5B & D). Compar-
ison of uptake in the area of the common portal vein in treated
mice showed a 32% average decrease in total radioactivity over
the three-day treatment period, although this did not reach
significance (P=0.12; Figure 5C & D). The number of worms
reported in Figure 5B and C were determined as described above
by perfusing mice after mPET imaging on day 4. The viability of
the worms was qualitatively assessed by trypan blue exclusion.
Worms recovered from the mouse that exhibited the largest
decreased in FDG uptake in the common portal vein (77%) were
dead (did not exclude trypan blue; mouse with 20 worms in
Figure 5).
Discussion
Our current understanding of the S. mansoni migration cycle in
the host is based on earlier studies in which radiolabeled
schistosomulae were injected into mice and tracked with
autoradiography [26]. Only in recent years have noninvasive
imaging technologies become available for small animal studies of
schistosomiasis. FMT was recently applied to schistosomiasis to
quantify adult worm burden [17]. While the results showed that
the number of worms in infected mice can be quantified using
near-infrared probes activated by proteases, only a limited range of
worm burdens was assessed and optical imaging techniques
currently cannot be applied in humans. In this work, we
investigated the possibility of PET imaging of S. mansoni in mice
as this technology is readily applicable to humans. Here we show
that FDG uptake in adult parasites both in vitro and in vivo
correlates with parasite numbers. We also demonstrate that adult
worms can be imaged in vivo using mPET to assess worm burden.
However, our ability to quantify worm burden by FDG-mPET was
limited in mice with low worm burden.
In vitro FDG uptake studies carried out on adult schistosomes first
showed that FDG uptake in five adult worms was greater than that
in single adult worms. Well counting measurements also showed
that the radioactivity levels in worms recovered from infected mice
after FDG mPET imaging strongly correlated with the number of
Figure 4. Quantitative analysis of the FDG-mPET images and
well-counting data in control and infected mice. (A) Relationship
between the total radioactivity within three-dimensional ROIs drawn
around the portal vein and/or areas of abnormal uptake in the liver and
the number of worms when considering all datasets (graph) or only
datasets obtained from mice with more than 50 worms (blue inset). (B)
Radioactivity levels measured by well counting as a function of the
number of worms. (C) Total radioactivity measured by mPET graphed as
a function of the total radioactivity measured by well counting.
doi:10.1371/journal.pntd.0000827.g004
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quantified by mPET imaging may correlate with the worm burden.
Furthermore, the lower FDG uptake in iodine-killed single worms
compared to untreated single worms suggested that FDG-mPET
may be useful in assessing the outcome of treatments such as
praziquantel. Theresidual radioactivityassociated with dead worms
in Figure 1 likely represents the inability to remove the
unmetabolized FDG following repeated washings.
To supplement the mPET data, we quantified worm burden by
assaying protease activity using FMT. We first imaged infected
mice 24 hours after Prosense 680 injection (Visen Medical Inc.;
Bedford, MA). The images revealed high fluorescence signal
coming from the liver of all mice, including uninfected animals.
This was observed in a previous study unrelated to schistosomiasis
comparing small molecular probes with the larger Prosense 680
and 750 probes and may be caused by the hepatic clearance of the
Figure 5. FDG-mPET imaging of praziquantel-treated mice. (A) mPET imaging performed before (Day 1) and after (Day 4) praziquantel
treatment. ROIs on the coronal sections chosen for display are outlined by a green dotted line. Intensity scale [0 (black) –2610
4 (white) nCi/cc]. (B)
Quantification of FDG uptake in the area of the common portal vein in untreated infected animals at day 1 and day 4 (* and **; Figure S1). (C)
Quantification of FDG uptake in the area of the common portal vein in infected animals before and after treatment. (D) Average change in FDG
uptake in treated and untreated mice relative to FDG uptake at day 1. Error bars represent the standard deviation.
doi:10.1371/journal.pntd.0000827.g005
In Vivo FDG-PET Imaging of Schistosomes
www.plosntds.org 7 September 2010 | Volume 4 | Issue 9 | e827released fluorochromes [27]. Furthermore, high levels of the
proteases that activate the Prosense probes used are expressed in
the liver. Because of this high background in the liver, only probe
accumulation in the lower abdomen was quantified. A linear
correlation between total probe amount and worm burden was
observed, but only in mice with less than 60 worms. Similar results
were demonstrated in another study, although only animals with
less than 35 worms were included [17]. This demonstrates the
presence of adult worms in the mesenteric vasculature, which was
confirmed at the time the worms were recovered. The poor
correlation in animals with higher worm burdens likely arises from
the presence of worms retained in the common portal vein and
adjacent liver parenchyma.
In contrast to FMT, FDG imaging showed relatively low FDG
uptake in the liver but considerable and variable FDG uptake in
the lower abdomen of all mice, regardless of the worm burden
(Figure S1). Autoradiography showed that most of the radioactiv-
ity in the lower abdomen was in the colon and was not associated
with schistosomes. Focal FDG uptake in normal gut can appear as
false lesions in PET scans of the abdomen in humans [28–30].
These foci of abnormal FDG uptake can be caused by metabolism
in the gut flora or by peristalsis for example. In heavily infected
animals, FDG uptake in the lower abdomen may also be
associated with innate inflammatory response either from products
released by worms or colonic flora from compromised integrity of
the gut wall. High uptake in the gut of control (uninfected) animals
and low uptake in the gut of some infected animals suggests that
gut motility and metabolism and a moderate immune response to
schistosomiasis infection may all be factors that contribute to FDG
uptake not associated with worms in the lower abdomen.
Moderate FDG uptake was observed in regions inferior to or
within the liver and total radioactivity levels within these regions
appeared to increase with the worm number. A linear correlation
between total radioactivity within these regions and the number of
worms was demonstrated across a wide range of infection burdens
(0–242 worms). This correlation was especially strong in mice with
high worm burden, suggesting that in heavily infected animals,
most worms remain in the common portal vein and in the liver
parenchyma. This was demonstrated by cryomicrotome imaging
and by dissection at the time of worm recovery. We speculate that
in mice with high infection burden, adults mature more slowly and
thus, proportionally fewer worm pairs migrate into the mesenteric
vasculature at the time the imaging studies were carried out (5–6
weeks after infection). FMT imaging, cryomicrotome imaging and
direct observations at the time of perfusion showed the presence of
worms in the mesenteric vasculature in heavily infected animals.
However, worms in the mesenteric vasculature are in insufficient
numbers to account for the large uptake of FDG observed on the
PET images. The low levels of radioactivity associated with worms
in the mesenteric vasculature could not be accurately and
consistently detected against the high FDG uptake in the lower
abdomen of some mice.
To further validate the mPET results, animals were treated with
praziquantel, an anti-schistosomal drug that targets adult worms.
The FDG signal measured in treated animals decreased after
three days of treatment while that in untreated animals increased
over the same period. The variability in change of FDG uptake in
the region of the common portal vein in response to praziquantel
is likely due to the use of athymic nude mice that can result in
impaired parasite killing since praziquantel treatment efficacy has
been shown to be dependent upon an intact host immune
response [31]. Indeed variable efficacy of drug treatment was
noted in trypan blue exclusion studies performed on the worms
after perfusion. The analysis of the results is further complicated
by the fact that the number of worms prior to the start of
praziquantel treatment is unknown and thus, treatment efficacy
cannot be accurately assessed. Nevertheless, these results suggest
that, with some improvements in the technique and recovery of
worms in the lower abdomen, PET imaging may be useful to
assess treatment outcome using an individual as its own control
and ROI-based analysis to assess the number of worms after
treatment.
The high non-specific FDG uptake in the colon and, to a lesser
extent, small intestines, that limited our ability to detect
schistosomes in the mesentery in infected mice may not be such
an issue when performing FDG-PET imaging studies in human
patients with schistosomiasis. Methods such as colon cleansing by
isosmotic solution taken the evening prior to examination,
intravenous hydration with 0.45% saline and cleansing of the
urinary tract and bladder during scanning were shown to yield
artifact-free PET images in humans [30]. Such methods could be
applied to decrease non-specific uptake in the gut and allow better
detection of worms in the mesentery. Another potential back-
ground issue for these studies is that activated immune cells in
granulomas formed in response to ova deposition may also uptake
FDG and affect quantification of the worm burden in humans. T-
cell-deficient mice were used in these experiments to avoid an
immune response from the host. Previous studies reported no
statistically significant difference in size between worms developing
in nude mice and controls [32]. Nude mice also exhibited
suppressed granuloma formation and reduced morbidity, further
justifying our choice of animal model [33]. We imaged all mice 5–
6 weeks post-infection, at a point in development when some
worms begin egg release and most worms have matured to full
adult stage. Performing these experiments in immunocompetent
mice should be achievable since studies conducted in immuno-
competent rats showed that treatment with a single dose of
methylprednisolone resulted in decreased FDG uptake in
granulomas [34]. Such a strategy could be used to distinguish
between inflammatory lesions and schistosomes on FDG-PET
images.
Finally, the mPET scanner used in our experiments has a spatial
resolution of approximately 1.84 mm, but other small animal
scanners have reported spatial resolutions as low as 0.7 mm for 10-
cm detector ring radius [35,24]. Adult schistosomes range from
0.6–1.1 cm in the thicker males (0.07 cm in diameter) and 1.2–
1.6 cm for the thinner females (0.016 cm in diameter) [36].
Human PET scanners currently have a spatial resolution of
approximately 5 mm, but scanners with 2 mm isotropic spatial
resolution across the field of view are available [37]. While the
spatial resolution of animal or human PET scanners may not be
high enough to resolve individual worms, the high sensitivity of
this imaging modality may allow non-invasive quantification of the
worm burden in infected mice and man through region-based
quantitative analysis.
In conclusion, these studies verified the hypothesis that high
glucose metabolism in S. mansoni allows for detection with FDG-
mPET and quantification of the disease burden in vivo. Because of
the possibility to apply PET technology to humans to support the
development of new diagnostic tools and for vaccine research, we
believe FDG-PET imaging of schistosomiasis should be further
investigated. Studies moving forward will include efforts to
minimize non-specific radiotracer uptake in the gut (e.g. using
antibiotic cocktails, laxatives or combinations of both) and FDG-
mPET imaging studies in immunocompetent rodent models
infected with schistosomiasis. Finally efforts are already underway
to develop radiotracers more specific for parasites, including
radiolabeled praziquantel.
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Figure S1 FDG mPET imaging of control and infected mice.
Three-dimensional ROIs were manually drawn around the portal
vein of all animals and, when observable, in regions of increased
FDG uptake in the liver. Representative coronal sections from
every animal used in the quantitative study are shown. Intensity
scale [0 (black) - 2610
4 (white) nCi/cc]. ROI outlines are shown in
dotted green lines. *Infected mice imaged on day 1. **Corre-
sponding untreated infected mouse imaged on day 4.
{ The ROI
was drawn around a region of increased FDG uptake inferior to
the liver that was not connected to the colon as determined by
careful examination of all adjacent coronal sections.
Found at: doi:10.1371/journal.pntd.0000827.s001 (5.00 MB TIF)
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